Table 3. The largest randomized clinical trials comparing standard D2-dissection versus extended D2 plus PAND dissection.
| Randomized trial | Country | Intervention | Operative morbidity | Operative mortality | 5-year survival |
|---|---|---|---|---|---|
| JCOG17,35 | Japan | D2 (n=264) | 20.9% | 0.8% | 69.2% |
| D2 plus PAND* (n=260) | 28.1% | 0.8% | 70.3% | ||
| Polish46 | Poland | D2 (n=141) | 27.7% | 4.9% | _ |
| D2 plus PAND (n=134) | 21.6% | 2.2% | |||
| East Asian42,45 | Multicenter° | D2 (n=135) | 26% | 0.7% | 52.6% |
| D2 plus PAND (n=134) | 39% | 3.7% | 55.4% |
JCOG, Japan Clinical Oncology Group.
*
Paraaortic lymph node dissection;
°
Japan, Korea, and Chinese Taiwan area.